IMMY - Imprimis Pharmaceuticals, Inc.
| Previous Close | 2.95 |
| Open | 2.95 |
| Bid | 2.56 x 900 |
| Ask | 3.10 x 1200 |
| Day's Range | 2.87 - 3.09 |
| 52 Week Range | 1.35 - 3.38 |
| Volume | 213,834 |
| Avg. Volume | 116,680 |
| Market Cap | 63.78M |
| Beta | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.46 |
| Earnings Date | Nov 12, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- GlobeNewswire•4 days ago
Consolidated Research: 2018 Summary Expectations for FTD Companies, PRA Group, Equity Bancshares, ConforMIS, Immune Design, and Imprimis Pharmaceuticals — Fundamental Analysis, Key Performance Indications
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FTD ...
- Associated Press•13 days ago
Imprimis: 2Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had net income of 12 cents. The pharmaceutical and drug compounding company posted revenue of $10.4 million in the period. In the final minutes ...
- PR Newswire•13 days ago
Imprimis Pharmaceuticals Announces Second Quarter 2018 Results
SAN DIEGO , Aug. 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the second quarter 2018. Notable Highlights from the Second Quarter of 2018: Revenues of ...
- ACCESSWIRE•13 days ago
Imprimis Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern ...
- PR Newswire•18 days ago
Imprimis Announces Multi-Center Clinical Trial for Dropless® TriMoxi™ (Triamcinolone Acetonide-Moxifloxacin for injection) Formulation in Canada
Study to assess drug safety, patient preference and pharmacoeconomic measures in 200 routine cataract surgeries SAN DIEGO , Aug. 1, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) through ...
- GlobeNewswire•19 days ago
Imprimis Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 6, 2018
Imprimis Pharmaceuticals, Inc. (IMMY) today announced it will release second quarter 2018 financial results after the close of trading on Monday, August 6, 2018. The company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (877) 407-8031 for domestic callers or (201) 689-8031 for international callers. To listen to the webcast, please click here or visit the investor relations section of the Imprimis website by clicking here. A dial in replay of the call will be available until September 6, 2018. To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 34365. The webcast replay will be available until November 6, 2018.
- PR Newswire•last month
Imprimis Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference on August 9, 2018
SAN DIEGO , July 18, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum ...
- PR Newswire•3 months ago
ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery
SAN DIEGO, May 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.'s (IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published in the Journal of Cataract and Refractive Surgery in January 2018, which followed 483 eyes with glaucoma that were undergoing cataract surgery with concomitant trabecular microbypass stent insertion. The study was initially presented at the American Society of Cataract and Refractive Surgery (ASCRS) and examines post-surgery outcomes for patients receiving an intravitreal injection of steroid and antibiotics at the time of surgery compared with a standard drop regimen following surgery. All study participants were diagnosed with primary open-angle glaucoma and received a glaucoma stent at the time of surgery in parallel with the cataract surgery procedure. The study group of 234 eyes received an intravitreal injection (pars plana) of 0.2 mL of Dropless®, a combination of steroid and antibiotics, at the time of surgery. The control group of 249 eyes received a standard topical regimen postoperatively.
- ACCESSWIRE•3 months ago
Blog Exposure - Emergent BioSolutions and Profectus BioSciences Receive Contract from CEPI to Develop Nipah Virus Vaccine
LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EBS as the Company's latest news hit the wire. On May 24, 2018, the Company announced that the Coalition for Epidemic Preparedness Innovations (CEPI) has provided up to $25 million to the Company and Profectus BioSciences, Inc. ("Profectus") to advance the development and manufacture of a vaccine against the Nipah virus (NiV), a bat-borne virus that can spread to both humans and livestock. Active-Investors.com is currently working on the research report for Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which also belongs to the Healthcare sector as the Company Emergent BioSolutions.
- Associated Press•3 months ago
Imprimis: 1Q Earnings Snapshot
The San Diego-based company said it had a loss of 17 cents per share. The pharmaceutical and drug compounding company posted revenue of $8.9 million in the period. In the final minutes of trading on Tuesday, ...
- PR Newswire•3 months ago
Imprimis Pharmaceuticals Announces First Quarter 2018 Results
SAN DIEGO, May 15, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY) today reported financial results for the first quarter 2018. Imprimis Pharmaceuticals has retained ownership of 3.5 million shares of Eton Pharmaceuticals common stock and 3.5 million shares of Surface Pharmaceuticals common stock. In addition, Imprimis owns mid-single digit royalty rights on all contributed drugs. Imprimis retains royalty rights on two patent-pending sterile injectable drug candidates contributed to Eton, one targeting infantile spasms and the other targeting Peyronie's Disease. Imprimis retains royalty rights on three patent-pending drug candidates contributed to Surface, two are topical eye drop drug candidates, the third is an oral capsule, all of which target certain ocular surface diseases.
- PR Newswire•3 months ago
Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners
SAN DIEGO, and PLEASANTON, Calif., May 15, 2018 /PRNewswire/ -- Surface Pharmaceuticals, Inc., an affiliated company of Imprimis Pharmaceuticals, Inc. (IMMY), today announced it has entered into a definitive stock purchase agreement with an affiliate of Flying L Partners to raise proceeds of up to approximately $20 million in a private placement of its Series A preferred stock. Surface Pharmaceuticals intends to use the proceeds of the Series A financing to advance its clinical development programs focused on ocular surface disease, including Dry Eye Disease treatments, by seeking FDA approval for three drug candidates for up to five indications, as well as for general corporate purposes.
- Simply Wall St.•4 months ago
Imprimis Pharmaceuticals Inc (NASDAQ:IMMY): Time For A Financial Health Check
While small-cap stocks, such as Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) with its market cap of US$47.54M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
- Simply Wall St.•4 months ago
Does Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Salary Compare Well With Others?
Mark Baum took the helm as Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO and grew market cap to US$45.45M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
- PR Newswire•4 months ago
Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting
New combination topical drops and other cGMP (current good manufacturing practices) formulations will be showcased SAN DIEGO , April 10, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), ...
- PR Newswire•5 months ago
Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation
SAN DIEGO, March 27, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it has secured a patent covering the company's innovative MKO (midazolam, ketamine, and ondansetron) Melt® compounded formulation from the US Patent and Trademark office. US Patent 9,918,993 B2 entitled "Pharmaceutical compositions for anesthesiological applications" was issued on March 20, 2018. Imprimis believes that beyond cataract surgery, there are likely more than 100 million annual procedures in the US ranging from dental, obstetric and gynecological, medical imaging procedures (such as MRIs and CAT scans), vasectomies, colonoscopies, dermatological, plastics procedures, orthopedic, otolaryngological, podiatry, emergency room, urology, and psychiatric that may benefit from an IV-free and opioid-free formulation.
- Associated Press•5 months ago
Imprimis reports 4Q loss
The San Diego-based company said it had a loss of 13 cents per share. The pharmaceutical and drug compounding company posted revenue of $7.3 million in the period. For the year, the company reported that ...
- PR Newswire•5 months ago
Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results
SAN DIEGO , March 8, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the fourth quarter 2017. Notable ...
- ACCESSWIRE•5 months ago
Imprimis Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018 at 4:30 PM Eastern ...
- ACCESSWIRE•5 months ago
Wired News – Imprimis Pharma Launched New Program for Custom Compounded Ophthalmic Medications
Stock Monitor: Akcea Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 08, 2018 / Active-Investors.com has just released a free research report on Imprimis Pharma, Inc. (NASDAQ: IMMY ...
- PR Newswire•5 months ago
Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018
SAN DIEGO , March 7, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum ...
- PR Newswire•5 months ago
Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations
SAN DIEGO, March 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmic-focused pharmaceutical company, today announced that it has launched a new program to provide ophthalmologists and optometrists with custom compounded ophthalmic medications that are increasingly difficult to find and typically needed on an urgent basis. The goal of this program is to provide high-quality compounded medications from an Imprimis FDA-inspected facility and ship it within 24-48 hours. Imprimis intends to make this program available in all 50 US states. "Recent changes in ophthalmic compounding has made it such a challenge to access critical compounded medications, especially for infectious keratitis, where urgent care is essential," stated Marjan Farid, MD, Director of Cornea, Cataract, and Refractive Surgery, Vice-Chair of Ophthalmic Faculty at the Gavin Herbert Eye Institute, University of California Irvine.
